Lyfegen and EVERSANA Collaborate to Revolutionize Drug Pricing and Access with AI-Driven Insights
Basel, Switzerland –28, January 2025 – Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformat…
Basel, Switzerland –28, January 2025 – Lyfegen, a global innovator in drug market access, pricing, and rebate management, has announced a transformat…
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s...
Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed round Since the successful release of the largest AI foundation model for pathology in July, the comp...
The U.S. Food and Drug Administration (FDA) released a draft guidance titled "Artificial Intelligence-Enabled Device Software Functions: Lifecycle Man…
AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind conversational AI behavioral agent for weight loss and maintenance, trained using real-world experience in over 150,...
The Austin-based startup founded by industry leaders accelerates time to market, enhances efficiency, and reduces costs for pharmaceutical companies through AI-driven automation of medical, legal, and regulatory reviewsAUSTIN, Texas--(BUSINESS WIRE)--...
Axonal's Agentic AI Collaborative Workspace leverages multi-agent technology to shorten the time from insights to actions and streamline commercialization.BOCA RATON, Fla.--(BUSINESS WIRE)--Axonal.AI today unveiled its groundbreaking platform, designe...
At the close of Frontiers Health 2024, we had the pleasure of speaking with Luca Quagliata, VP and Global Head of Medical and Scientific Affairs from …
Multi-institutional study presented at the SITC annual meeting highlights the ability of Onc.AI’s imaging-based biomarker to improve identification of long-term survivors at first follow up (HR 0.33). SAN CARLOS, Calif. & WATERLOO, Ontario--(BUSINESS ...
In 2021, over 355,900 children worldwide were diagnosed with type 1 diabetes, a number expected to rise significantly by 2050. Early diagnosis is cruc…